Ascletis starts Phase III ASC30 obesity trials targeting 4,600 participants
AI Summary- Ascletis dosed the first participant in its global Phase III ASC30 program.
- Approximately 4,600 participants will receive 20 mg, 40 mg, 60 mg, or placebo.
- Ascletis expects topline results in the third quarter of 2028.